17 research outputs found
Kernel quality and composition of hazelnut (Corylus avellana L.) cultivars
No full textIn order to characterize the influence of nut composition on quality, seventeen cultivars grown in Viterbo were analysed in 2000-2001. Quantitative and qualitative determinations of sugars, organic acids, lipids and vitamins were carried out. Total polyphenols in the pellicle and in the seed were measured. The sensory profiles of six cultivars (‘Tonda Gentile delle Langhe’, ‘Tonda di Giffoni’, ‘Tonda Gentile Romana’, ‘Mortarella’, ‘Nocchione’ and ‘Tombul’) were examined. Fatty acid composition and level of tocopherolic and non tocopherolic antioxidant confirmed the nutritional and dietetic value of the nuts. Polyphenols were mainly concentrated in the perisperm. Sensory analysis was able to reveal varietal differences for attributes related to taste and flavour. A positive relationship between sweetness scores and sugar concentration was observed
Biochemical pattern of rat liver during and after treatment with 1,2-dichloropropane
No full text1,2-Dichloropropane (1,2 D) induces liver acute toxicity. In chronic experimental treatment of rats, biochemical and histological pattern shows a hyperplastic damage of the liver cell. The present work studies the behaviour of the liver metabolic pattern during and after treatment with 1,2 D. Male, albino, Wistar rats, starting weight 200±10 grams, were treated i.p. for 4 weeks (5 days/week, 2 days without treatment) with 0 and 250 mg/kg b.w. of 1,2 D dissolved in corn oil. The rats were sacrificed after 5, 10, 15 and 20 treatments, and two months after suspension of the treatment. After the sacrifice, the liver was drawed and prepared for determination of Cytochrome P-450 activity (Cyt P-450), reduced glutathione content (GSH), and glutathione S-transferases activity (GST). GSH content shows a statistically significant increase after ten treatments, GST activity significantly increases after 15 treatments, and Cyt P-450 significantly decreases after 20 treatments. Phase II components of liver metabolism are then firstly involved by 1,2 D. The biochemical pattern is indicative of a hyperplastic evolution of the liver cell as it is confirmed by histology. Suspension of the treatment shows a return to normal values of Phase I and Phase II components. These results shows after the suspension of the treatment a tendency to repair of the lesions induced by 1,2 D
gamma-Glutamyltransferase in urine as an early index of kidney involvement in cadmium exposure.
No full textno abstract availabl
THE IMPLEMENTATION OF MORNING FUN EXTRACURRICULAR PROGRAM IN MA MATHOLIUL HUDA TROSO PECANGAAN JEPARA
No full textThis study aims to describe the implementation of the morning fun extracurricular program to improve English learning vocabulary in MA. Matholiul Huda Troso Pecangaan Jepara. This research was carried out from Tuesday, August 1st to August 30th, 2022. This study used a case study approach. In this study, there were 25 students as sources of objects who later be assessed whether the application of this morning fun program could make a tool which was to able to develop the vocabulary of students at MA. Matholiul Huda Troso. Data collection was carried out by interviews and observations and the researcher wa as the controller in this study. Data collection in this documentation study also uses pretest and posttest. This study also used gradual observations to see whether the morning fun program was successful or not in developing vocabulary. In analyzing the data, the researcher greatly reduces the data because there is a lot of data obtained. Then the author displayed the data based on needs and reality. The results of these two things are refined by a conclusion and it can be concluded that this morning fun program can increase students' vocabulary in MA. Matholiul Huda Troso and be used as a consideration to increase vocabulary in English
AUMENTATO DIAMETRO DELL'AORTA ADDOMINALE NELLE DONNE CON SINDROME DELL'OVAIO POLICISTICO
No full text
Abstract P4-21-34: Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy
No full textAbstract
Background: The combination of taxanes with trastuzumab (H) and pertuzumab (P) for first line treatment of HER2-positive metastatic breast cancer (MBC) is associated with improved progression-free survival (PFS) and overall survival (OS). Treatment per physician's choice with anti-HER2 therapy after second line therapy is associated with a median PFS of 3 months. While continued use of H in therapeutic combinations after progression on H-based therapy is common, the efficacy of continuing HP-based treatment after progression on P-based therapy is unknown.
Methods: This is a single arm phase II trial of gemcitabine (G) with HP. Eligible patients had HER2-positive (IHC 3+ or FISH ≥ 2.0) MBC with prior HP-based treatment and ≤ 3 prior chemotherapies. Patients received G (1200 mg/m2) on days 1 and 8 of a q 3 week (w) cycle, and H (8 mg/kg load → 6 mg/kg) and P (840 mg load → 420 mg) q3w. The primary endpoint is PFS at 3 months. Secondary endpoints include OS, safety and tolerability. An exploratory endpoint is to compare PFS by RECIST criteria versus 18-F FDG-PET response criteria. Using a Simon optimal 2-stage design, 21 patients were enrolled in stage 1. The successful 3-month PFS rate for stage 1 was set at 57% to allow accrual to stage 2 for a total of 45 patients. The study therapy will be considered successful if at least 27/45 (60%) patients are progression free at 3 months.
Results: As of June 9, 2016, 28 patients are enrolled; 21 are evaluable at 3 months and 7 have not had 3-month evaluation. At 3 months, 16/21 (76%) are progression free; 5 patients have progressed. The 3 month-PFS results for evaluable patients will be updated. There are no cardiac or febrile neutropenic events to date. Initially, 5 of 22 (23%) patients required G dose reduction (4 due to grade 3 neutropenia and 1 due to grade 3 vomiting) and the study was amended to lower initial G dose to 1000 mg/m2.
Conclusions: The preliminary 3 month-PFS is 76% (95% CI 55% to 89%) in evaluable patients, and updated data will be presented. These findings suggest clinical benefit when P is continued beyond progression.
Citation Format: Iyengar NM, Smyth L, Lake D, Gucalp A, Singh JC, Traina TA, DeFusco P, Dickler MN, Fornier MN, Goldfarb S, Jhaveri K, Modi S, Troso-Sandoval T, Argolo D, Jack K, Ulaner G, Jochelson M, Baselga J, Norton L, Hudis CA, Dang CT. Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-21-34.</jats:p
